We don't test cells.
We read them.
Oncoptic's multi-scale optical platform interrogates cells — from population-level signal down to a single cell — extracting structural, mechanical, and functional properties that no single existing test can see. Paired with an AI-enabled SaMD, it turns that signal into a diagnostic and therapeutic tool: label-free, fast, low-cost, and built for the point of care.
A world where disease is seen at the cell — not after it's grown, spread, or progressed.
Today's diagnostics miss what happens inside the cell
Current approaches provide valuable information, but critical challenges remain.
Cellular blind spots
Limited understanding of individual cellular differences.
Detection comes late
The need for more precise and earlier disease detection persists.
Complex workflows
Diagnostic pipelines are slow, fragmented, and hard to scale.
Hard to monitor
Tracking disease progression and treatment response remains difficult.
Built at the intersection of four fields most companies only touch one of
Biology
Knowing what cellular signal actually matters.
Optics
A novel sensing architecture built to capture it.
Signal Processing
Resolving raw optical signal into usable structure.
AI
An AI-enabled SaMD that turns signal into insight.
Most tests look at what's in a cell. We read what a cell is.
Structure. Mechanics. How it behaves. Captured optically — without stains, without destroying the sample. That opens applications existing tools can't reach: catching cancer earlier, and measuring how well a CAR-T therapy is actually working, cell by cell.
Why it matters
The team
Scientists and engineers from MIT, Harvard, Columbia, and leading industry labs.
Recognized internationally
The core technology has been recognized with the Nikola Tesla Award, the European Academy of Sciences Award, the US Star Award, and other international honors.
Let's redefine early detection together
Whether you're a clinician, researcher, investor, or potential teammate — we'd love to talk.
Get in touch